Opus Genetics (IRD) Interest Expenses (2020 - 2026)

Opus Genetics (IRD) posted quarterly Interest Expenses of $100000.0 for Q1 2026, little changed quarter-over-quarter from $100000.0 in Q3 2025.

Analysis

Opus Genetics (IRD) Interest Expenses (2020 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Interest Expenses for 14 consecutive years, with $100000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Interest Expenses changed N/A year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $200000.0 (changed N/A YoY), while the FY2025 annual figure was $40.0 million, changed N/A from the prior year.
Interest Expenses held at $100000.0 in Q1 2026 per IRD's latest filing, from $100000.0 in the prior quarter.
Across five years, Interest Expenses topped out at $100000.0 in Q3 2025 and bottomed at $4000.0 in Q2 2022.
Historically, Interest Expenses has averaged $52250.0 across 3 years, with a median of $52500.0 in 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-1.00 Mn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	23.78 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	39.74 Mn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	82.05 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	93.62 Mn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	20.27 Mn
10	Opus Genetics	446.86 Mn	358.05 Mn	-	-

Historic Data

Download Data